Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
American Innovation and R&D Competitiveness Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
American Innovation and R&D Competitiveness Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
GENENTECH INC via GENENTECH, INC
2021 · third_quarter · Q3
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
Source: Senate LDA
H.R. 1304, the American Innovation and R&D Competitiveness Act) and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives
American Innovation and R&D Competitiveness Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R. 1304, the American Innovation and R&D Competitiveness Act) and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives
American Innovation and R&D Competitiveness Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 S.Con.Res 14- FY2022 Budget Resolution H.R. 1319 - American Rescue Plan Act, 2021 H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight - Support for increased investments to address antimicrobial resistance. - Deficit reduction, reconciliation
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 S.4796, The Fair Care Act of 2020 H.R.5260 - Reduced Costs and Continued Cures Act - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value - Issues related to the 340B Drug Discount Program
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Affordable Prescriptions for Patients Through Promoting Competition Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
Client: GENENTECH INC · Firm: GENENTECH, INC
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act
Client: GENENTECH INC · Firm: GENENTECH, INC
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 S.4796, The Fair Care Act of 2020 H.R.5260 - Reduced Costs and Continued Cures Act - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value - Issues related to the 340B Drug Discount Program
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
To enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R. 3788, the Protecting American Innovation Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foriegn patents - Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
National Defense Authorization Act for Fiscal Year 2022
Client: GENENTECH INC · Firm: GENENTECH, INC
S.2782 - National Defense Authorization Act for Fiscal Year 2022 H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - Issues related to pharmaceutical supply chains and related security issues
Strengthening Innovation in Medicare and Medicaid Act
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 S.4796, The Fair Care Act of 2020 H.R.5260 - Reduced Costs and Continued Cures Act - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value - Issues related to the 340B Drug Discount Program
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
Extending Government Funding and Delivering Emergency Assistance Act
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 S.Con.Res 14- FY2022 Budget Resolution H.R. 1319 - American Rescue Plan Act, 2021 H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight - Support for increased investments to address antimicrobial resistance. - Deficit reduction, reconciliation
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 S.Con.Res 14- FY2022 Budget Resolution H.R. 1319 - American Rescue Plan Act, 2021 H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight - Support for increased investments to address antimicrobial resistance. - Deficit reduction, reconciliation
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
Affordable Prescriptions for Patients Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Affordable Prescriptions for Patients Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 S.4796, The Fair Care Act of 2020 H.R.5260 - Reduced Costs and Continued Cures Act - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value - Issues related to the 340B Drug Discount Program
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Acting on the Annual Duplication Report Act of 2021
Client: GENENTECH INC · Firm: GENENTECH, INC
S.2782 - National Defense Authorization Act for Fiscal Year 2022 H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - Issues related to pharmaceutical supply chains and related security issues
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Protect American Taxpayer Dollars from Illegal Immigration Act
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R. 1304, the American Innovation and R&D Competitiveness Act) and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
H.R. 1304, the American Innovation and R&D Competitiveness Act) and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
A bill to enable certain hospitals that were participating in or applied for the drug discount program under section 340B of the Public Health Service Act prior to the COVID-19 public health emergency to temporarily maintain eligibility for such program, and for other purposes.
Client: GENENTECH INC · Firm: GENENTECH, INC
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 658- ADAPT Act- Accelerated Drug Approval for Prescription Therapies H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5376 - Build Back Better Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to health equity, diversity, and inclusion in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and access - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data - Issues relating to screening and diagnostics
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 S.4796, The Fair Care Act of 2020 H.R.5260 - Reduced Costs and Continued Cures Act - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value - Issues related to the 340B Drug Discount Program
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 S.Con.Res 14- FY2022 Budget Resolution H.R. 1319 - American Rescue Plan Act, 2021 H.R. 5402 - FY 2022 Labor, HHS, Education, Agriculture, Rural Development, Energy and Water Development, Financial Services and General Government, Interior, Environment, Military Construction, Veterans Affairs, Transportation, and Housing and Urban Development Appropriations Act, 2022 H.R. 5305 Extending Government Funding and Delivering Emergency Assistance Act - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight - Support for increased investments to address antimicrobial resistance. - Deficit reduction, reconciliation
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act H.R.5260 - Reduced Costs and Continued Cures Act H.R. 5125, the Strengthening Innovation in Medicare and Medicaid Act H.R. 5376 - Build Back Better Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act S. 2774 - Pride in Patent Ownership Act S. 2773 - Unleashing American Innovators Act S. 2891 - Restoring the America Invents Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
S.2782 - National Defense Authorization Act for Fiscal Year 2022 H.R.4350 - National Defense Authorization Act for Fiscal Year 2022 - Issues related to pharmaceutical supply chains and related security issues
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, Treasury, Dept of, U.S. Trade Representative (USTR)
GENENTECH INC via GENENTECH, INC
2021 · first_quarter · 1A
- Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foreign patents
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
H.R. 1304, the American Innovation and R&D Competitiveness Act) and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives
- Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
GENENTECH INC via GENENTECH, INC
2021 · second_quarter · Q2
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 S.2076/H.R. 3932 PASTEUR Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 S.1773 - Prescription Drug Pricing Dashboard Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R. 3788, the Protecting American Innovation Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry including the TRIPS IP Waiver - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foriegn patents - Issues related to WTO Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS)
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) H.R. 2113 - The Prescription Drug STAR Act H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 4199, Prescription Drug Pricing Reduction Act of 2020 S.551 - REFUND Act of 2019 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319, American Rescue Plan Act of 2021 H.R. 2163/S. 464 - Safe Step Act S.4796, The Fair Care Act of 2020 S.2076/H.R. 3932 PASTEUR Act S.1773 - Prescription Drug Pricing Dashboard Act S. 773/H.R. 3203 - [No official title] Related to The 340B Drug Discount Program S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act S. 3300, Data Protection Act of 2021 H.R.3801, Data Localization Compendium Legislation - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues related to patient assistance and acces - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R. 1304, the American Innovation and R&D Competitiveness Act and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives - Issues related to corporate tax rate as well as international taxation, including foreign-derived intangible income
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act H.R.19, Lower Costs, More Cures Act of 2021 S.2164 - Lower Costs, More Cures Act (LCMCA) S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
S.1435 - Affordable Prescriptions for Patients Act of 2021 H.R.2873 - Affordable Prescriptions for Patients Through Promoting Competition Act of 2021 H.R.2884 - Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act - Intellectual property and process patent issues - Patent litigation reform - PTAB and IPR processes - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR)
GENENTECH INC via GENENTECH, INC
2021 · first_quarter · Q1
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
- Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foreign patents
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.133 - Consolidated Appropriations Act, 2021 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development - Issues related to drug development including PDUFA and Cures 2.0
H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act S. 3013, Encouraging Innovative Benefit Design to Lower Costs for Seniors Act H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act H.R. 1319, The American Rescue Plan of 2021 H.R./S. XX American Jobs Plan S. 920 - The Affordable and Safe Prescription Drug Importation Act S. 909 - The Prescription Drug Price Relief Act S. 908 - The Medicare Drug Price Negotiation Act S.4796, The Fair Care Act of 2020 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B and general reference pricing - Issues related to CMMI
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R. 3 - Lower Drug Costs Now Act of 2019 H.R.19, Lower Costs, More Cures Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499 - Protecting Consumer Access to Generic Drugs Act of 2019 S.3129 - Lower Costs, More Cures Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S. 2543, Prescription Drug Pricing Reduction Act of 2019 S.551 - REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 S.1712/H.R.4100 - DISARM Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act H.R. 1319 , American Rescue Plan Act of 2021 H.R. xx - Safe Step Act (no bill number yet) S.4796, The Fair Care Act of 2020 H.R.1966/S.946 - Henrietta Lacks Enhancing Cancer Research Act of 2019 H.R.133 - Consolidated Appropriations Act, 2021, 116th Congress (2019-2020) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to diversity in clinical trials - Issues related to advanced development and procurement of medical countermeasures (MCMs) - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R. 1304, the American Innovation and R&D Competitiveness Act) and S. 749 American Innovation and Jobs Act - Issues related to R&D tax deductions and expense amortization - Issues related to supply chain incentives
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program S.4796, The Fair Care Act of 2020 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act, 2020 S. 3548 - CARES Act (Coronavirus Stimulus 3), 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 H.R. 1319 - American Rescue Plan Act, 2021 H.R. XX - FY 2022 Labor, HHS, Education and Related Agencies Appropriations H.R. XX - FY 2022 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation - Issues related to FDA and HHS program funding for the FY22 Labor, HHS, Education and Related Agencies, and FY22 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Funding for FDA e-labeling rule implementation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues related to 340B program oversight
- Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
GENENTECH INC via GENENTECH, INC
2020 · fourth_quarter · 4A
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foriegn patents
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act (HCR) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Ac - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
S. 1224, Stop STALLING Act S. 1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 3991-Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133--Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 1503 - the Orange Book Transparency Act; and H.R. 1520 - Orange Book Transparency Act of 2019; H.R. 3 - Lower Drug Costs Now Act of 2019 - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.133 - Consolidated Appropriations Act, 2021 H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) H.R.133 - Consolidated Appropriations Act, 2021 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
GENENTECH INC via GENENTECH, INC
2020 · third_quarter · 3A
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 7288 Taxpayer Research and Coronavirus Knowledge (TRACK) Act H.R. 4398 Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency
GENENTECH INC via GENENTECH, INC
2020 · second_quarter · 2A
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
GENENTECH INC via GENENTECH, INC
2020 · first_quarter · 1A
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency
GENENTECH INC via GENENTECH, INC
2020 · fourth_quarter · Q4
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
GENENTECH INC via GENENTECH, INC
2020 · third_quarter · Q3
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency
GENENTECH INC via GENENTECH, INC
2020 · second_quarter · Q2
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
GENENTECH INC via GENENTECH, INC
2020 · first_quarter · Q1
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
GENENTECH INC via GENENTECH, INC
2019 · fourth_quarter · 4A
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
GENENTECH INC via GENENTECH, INC
2019 · third_quarter · 3A
Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization
GENENTECH INC via GENENTECH, INC
2019 · second_quarter · 2A
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
GENENTECH INC via GENENTECH, INC
2019 · fourth_quarter · Q4
- Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S.3013, Encourging Innovative Benefti Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B
GENENTECH INC via GENENTECH, INC
2019 · third_quarter · Q3
Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039
H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
GENENTECH INC via GENENTECH, INC
2019 · second_quarter · Q2
HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization
Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
GENENTECH INC via GENENTECH, INC
2019 · first_quarter · Q1
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to Right to Try - Issues related to antimicrobial and antiviral research and product development
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to Right to Try - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part D
GENENTECH INC via GENENTECH, INC
2018 · fourth_quarter · Q4
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to Right to Try - Issues related to drug importation - Issues related to Part D Medicare Program including coverage gap and other offsets
GENENTECH INC via GENENTECH, INC
2018 · third_quarter · Q3
Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) Issues related to Medicare and Medicaid coverage and reimbursement including Part B payment, step therapy policy proposal in Medicare Advantage, implementation of value-based reimbursement models Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars MACRA treatment and reimbursement of Part B drugs Issues related to Part D Medicare Program including coverage gap and other offsets
GENENTECH INC via GENENTECH, INC
2018 · second_quarter · Q2
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to drug pricing Medicare reimbursement for biosimilars MACRA treatment and reimbursement of Part B drugs Medicare payments for inpatient antimicrobials Issues related to Right to Try Issues related to drug importation Issues related to Part D Medicare Program including coverage gap and other offsets
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 Issues related to the 340B Drug Discount Program Issues relating to drug pricing Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement, and pricing. Issues related to healthcare legislation Issues related to public health protection including influenza development and preparedness
GENENTECH INC via GENENTECH, INC
2018 · first_quarter · Q1
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act. S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA). Policies relating to the 340B Drug Discount Program Development of Policies to advance antimicrobial research and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act. S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). Issues related to Medicare and Medicaid coverage and reimbursement Issues related to the 340B Drug Discount Program Issues related to RX drug pricing Medicare reimbursement for biosimilars MACRA treatment and reimbursement of Part B drugs Medicare payments for inpatient antimicrobials
GENENTECH INC via GENENTECH, INC
2017 · fourth_quarter · 4A
Trade Policy Issues. Trade Negotiations.
Drug Pricing Issues Prescription Drug User Fee Act reauthorization. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
Issues relating to drug pricing
GENENTECH INC via GENENTECH, INC
2017 · fourth_quarter · Q4
Issues relating to drug pricing
Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 S.204/H.R.878, Trickett Wendler Right to Try Act of 2017 H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes H.R.1370, Further Additional Continuing Appropriations Act, 2018 Pharmaceutical benefits for TRICARE beneficiaries Issues related to pharmaceutical drug pricing Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Pharmaceutical distribution and supply chain security American Health Care Act of 2017 Issues relating to biosimilar reimbursement
GENENTECH INC via GENENTECH, INC
2017 · third_quarter · Q3
FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations FY 2018, Consolidation Appropriations Act of 2017 (P.L. 115-31)
Education around issues relating to the 340B Drug Discount Program General education around policies related to Medicare Part B coverage and reimbursement CHIP Reauthorization Policies on drug reimportation Policies around drug pricing Medicare payment for inpatient antimicrobials
Issues related to Right to Try
GENENTECH INC via GENENTECH, INC
2017 · second_quarter · Q2
Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers. General education about policies impacting pharmaceutical development, approval, pricing and reimbursement S. 469 Affordable and Safe Prescription Drug Importation Act. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. Stockpiling of medical countermeasures in advance of a potential pandemic. H.R.1628, American Health Care Act of 2017/Better Care Reconciliation Act of 2017. H.R.2430/S.934, FDA Reauthorization Act of 2017, Prescription Drug User Fee Agreement Issues related to the 340B Program Issues related to the implementation of the follow-on biologics provisions in P.L. 111148 "Patient Protection and Affordable Care Act". Medicare Part B Demonstration Implementation issues related to the Distribution Quality, Security and Accountability Act (P.L. 113-54), HR6, 21st Century Cures Act, Issues related to Pharma supply chain, Senate HELP Innovation Project
340B Drug Discount Program.
GENENTECH INC via GENENTECH, INC
2017 · first_quarter · 1A
Intellectual Property and Process Patent Issues. Patent Litigation Reform.
Monitor Drug Safety and pedigree legislation. 340B Drug Discount Program.
Issues related to FDA and HHS program funding in the FY17 Labor, Health and Human Services, and Education and Related Agencies, and FY17 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriations bills.
GENENTECH INC via GENENTECH, INC
2017 · first_quarter · Q1
Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers. Policies related to the 340B Drug Discount Program. Drug pricing issues. HR 1628, The American Health Care Act. S. 469 Affordable and Safe Prescription Drug Importation Act. Prescription Drug User Fee Act Agreements. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. Issues related to the implementation of the follow-on biologics provisions in P.L. 111148 "Patient Protection and Affordable Care Act". Stockpiling of medical countermeasures in advance of a potential pandemic. Implementation of issues related to the Security and Accountability Act (P.L. 113-54); Issues related to Pharma supply chain.
Bioterrorism preparedness and development of medical countermeasures.
GENENTECH INC via GENENTECH, INC
2016 · fourth_quarter · Q4
H.R. 34 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Accountability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA". S.2912, Trickett Wendler Right to Try Act of 2016. Pandemic Preparedness and CDC strategic national stockpile H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Issues relating to CMMI proposed CMMI Part B demo (81 FR 13229) 340B drug discount program. H.R. 34 21st Century Cures Act. Implementation of Medicare Pharmaceutical coverage and reimbursement. Follow-on biologies and Medicare Physician Fee schedule rule to blend ASP for biosimilars. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
GENENTECH INC via GENENTECH, INC
2016 · third_quarter · Q3
S 3040/HR5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.
Intellectual Property and Process Patent Issues. General IP Issues; Patent Litigation Reform; Transpacific Partnership Agreement.
Issues relating to CMMI proposed CMMI Part B demo (81 FR 13229) 340B drug discount program. 21st Century Cures initiative. Implementation of Medicare Pharmaceutical coverage and reimbursement. Follow-on biologies and Medicare Physician Fee schedule rule to blend ASP for biosimilars. H.R.5122, To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
GENENTECH INC via GENENTECH, INC
2016 · second_quarter · Q2
H.R. 6 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Sccoubtability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA".
S.3040, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (Chile, Colombia, Peru, CAFTA-DR)
H.R.4549 - American Innovation and Competitiveness Act of 2019 - Issues related to the tax reform bill and implementation - Issues related to supply chain incentives
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation -Issues related to the International Pricing Index for Medicare Part B -Issues related to CMMI
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 7288 Taxpayer Research and Coronavirus Knowledge (TRACK) Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency Medical Supply Chain - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B - Issues related to CMMI
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement
- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Issues related to Intellectual property and process patent - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues
- Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.133 - Consolidated Appropriations Act, 2021 H.R. 4378 - Continuing Appropriations Act and Health Extenders Act H.R. 133 - Consolidated Appropriations Act, 2021 H.R. 8337 - Continuing Appropriations Act of 2021 - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
S. 1224, Stop STALLING Act S. 1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 3991-Affordable Prescriptions for Patients Through Improvements to Patent Litigation Act of 2019 H.R. 5133--Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 1503 - the Orange Book Transparency Act; and H.R. 1520 - Orange Book Transparency Act of 2019; H.R. 3 - Lower Drug Costs Now Act of 2019 - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Domestic and international compulsory licensing issues - March-in Rights - Product hopping - Orange and purple book disclosures - Hatch Waxman litigation - Trade secret protections
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 S.4760, The Pioneering Antimicrobial Subscriptions To End Up Surging Resistance Act of 2020 H.R.133 - Consolidated Appropriations Act, 2021 H.R. 6800 - The Heroes Act (HCR) S. 4626, SAFE DATA Act S. 3456, Consumer Data Privacy and Security Act H.R. 2013, Information Transparency & Personal Data Control Act S. 2968, Consumer Online Privacy Rights Ac - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency - Issues relating to privacy and securing the data of and personal information of consumers - Issues relating to medical research data
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (UK, Kenya, Chile, Colombia, Peru, CAFTA-DR) - Issues related to compulsory licensing of foriegn patents
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) H.R.133 - Consolidated Appropriations Act, 2021 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
Filing targets: HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Homeland Security, Dept of (DHS), Labor, Dept of (DOL), Patent & Trademark Office (PTO), SENATE, U.S. Trade Representative (USTR), White House Office
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement - Issues related to other Free Trade Agreements (Chile, Colombia, Peru, CAFTA-DR)
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S. 2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S. 3013, Encouraging Innovative Benefit Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 H.R. 2296 - More Efficient Tools to Realize Information for Consumers Act H.R. 5741- Strengthening Innovation in Medicare and Medicaid Act -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation -Issues related to the International Pricing Index for Medicare Part B -Issues related to CMMI
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
H.R.4549 - American Innovation and Competitiveness Act of 2019 - Issues related to the tax reform bill and implementation - Issues related to supply chain incentives
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act Pioneering Antimicrobial Subscriptions to End Upsurging Resistance (PASTEUR) Act (No bill number yet) - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
S.4049 - National Defense Authorization Act for Fiscal Year 2021 H.R.2500 - National Defense Authorization Act for Fiscal Year 2021 H.R. 6395, William M. (Mac) Thornberry National Defense Authorization Act for Fiscal Year 2021 - Issues related to pharmaceutical supply chains and related security issues
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 7288 Taxpayer Research and Coronavirus Knowledge (TRACK) Act H.R. 4398 Affordable Prescriptions for Patients Through Promoting Competition Act of 2019 H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement
- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.4100 - DISARM Act of 2019 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 H.R. 6443, Securing the National Supply Chain Act H.R. 6630, Securing Americas Critical Minerals Supply Chain Act H.R. 6690, Bring Entrepreneurial Advancements To Consumers Here In North America Act H.R. 6713, Furthering Our Recovery With American Research and Development H.R. 6863, COVID-19 Accountability Act H.R. 6903, Bring American Companies Home Act H.R. 6930, To mitigate drug shortages and provide incentives for maintaining, expanding, and relocating the manufacturing of active pharmaceutical ingredients, excipients, medical diagnostic devices, pharmaceuticals, and personal protective equipment in the United States, and for other purposes. H.R. 7505, American Innovation Act H.R. 7527, To rescue domestic medical manufacturing activity by providing incentives in economically distressed areas of the United States and its possessions. H.R. 7537, Infectious Disease Therapies Research and Innovation Act H.R. 7555, More Cures Act H.R. 7556, Start-ups for Cures Act S. 3593, Furthering Our Recovery With American Research and Development S. 3945, Bring Entrepreneurial Advancements to Consumers Here In North America (BEAT CHINA) Act S. 3827, Medical Supplies for Pandemics Act H.R. 4710, Pharmaceutical Independence Long-Term Readiness Reform Act H.R. 6731, Securing Americas Pharmaceutical Supply Chain Act S. 3432, Securing Americas Medicine Cabinet [SAM-C] Act S. 3478, Commission on Americas Medical Security Act S. 3538, Strengthening America's Supply Chain and National Security Act S. 3635, Protecting our Pharmaceutical Supply Chain from China Act (previously S. 3537) H.R. 6531, Medical Supplies for Pandemics Act H.R. 6876, To amend the Public Health Service Act to ensure that the contents of the Strategic National Stockpile remain in good working order and, as appropriate, conduct maintenance services on contents of the stockpile, and for other purposes. H.R. 6049, Medical Supply Chain Security Act H.R. 6062 - to amend certain provisions in the Federal Food, Drug, and Cosmetic Act relating to the discontinuance or interruption in the production of life-saving drugs so as to apply such provisions with respect to life-saving devices, and for other purposes H.R. 6080, Preventing Drug Shortages Act H.R. 6393, Strengthening America's Supply Chain and National Security Act H.R. 6660, Limit Ongoing Shortages and Stabilize Supply Act H.R. 6670, Prescription for American Drug Independence Act H.R. 6708, Securing Americas Medicine Cabinet Act H.R. 6885, Safe and Secure Medicine Supply for Hardworking Americans Act S. 2723, Mitigating Emergency Drug Shortages Act S. 3343, Medical Supply Chain Security Act S. 3780, Help Onshore Manufacturing Efficiencies for Drugs and Devices Act (HOME) Act S. 3781, Pharmaceutical Accountability, Responsibility, and Transparency (PART) Act S. 3942, Securing Americas Medical Supply Chain and Advancing the Production of Life Saving Medicines Act - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency Medical Supply Chain - Issues related to pharmaceutical supply chains - Issues related to reporting on location of origin of pharmaceutical products - Issues related to drug shortages - Issues related to pharmaceutical manufacturing
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 H.R. 7296, Medications Affordable by Preventing Pandemic Price Gouging Act (MMAPPP) Act of 2020 H.R. 7288 Taxpayer Research and Coronavirus Knowledge (TRACK) Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization - Issues related to prescription drug value
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value
S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book H.R. 1499, the Protecting Cok Continuity Act; H.R. 1503, the Orange Book Transparency Act;consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation - Patient access to Part B medicines during the COVID-19 public health emergency
- Issues related to Foreign Agents Registration Act (FARA including Disclosing Foreign Influence Act -H.R. 4170/S. 2039
S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act S.1416 - Affordable Prescriptions for Patients Act of 2019 - Issues related to Intellectual property and process patent - Patent litigation reform - IPR process - Section 101 Reform - Compulsory licensing issues
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 S. 3548 - CARES Act (Coronavirus Stimulus 3) H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development - Issues related to novel coronavirus and COVID-19 research and product development
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement
- Issues related to the tax reform bill and implementation - Issues related to supply chain incentives
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and the FY2020 Consolidated measure. Reimbursement and vial size issues. H.R.6074 - Coronavirus Preparedness and Response Supplemental Appropriations Act, 2020 H.R.6201 - Families First Coronavirus Response Act S. 3548 - CARES Act (Coronavirus Stimulus 3) - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills - Strategic National Stockpile (SNS) Funding and Oversight - Patient access to Part B medicines during the COVID-19 public health emergency
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 Issues - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement
- Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
H.R.3 - Lower Drug Costs Now Act of 2019 S.977 - Transparent Drug Pricing Act of 2019 S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. S.2543, Prescription Drug Pricing Reduction Act of 2019. H.R.19, Lower Costs, More Cures Act of 2019. S.3013, Encourging Innovative Benefti Design to Lowes Costs for Seniors Act S. 3129, Lower Cost, More Cures Act of 2019 - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part B
H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
H.R.3 - Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Act (PDPRA) of 2019 S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization
S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part D
S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Issues related to​ Foreign Agents Registration Act (FARA including​ Disclosing Foreign Influence Act -H.R. 4170/S. 2039
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019. S.551, REFUND Act of 2019 Issues - Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Issues related to prescription drug value
H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry - Issues related to the United States-Mexico-Canada Agreement
H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.340- CREATES Act of 2019 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; H.R.3: Lower Drug Costs Now Act of 2019 S.1895, Lower Health Care Costs Act of 2019 S.551, REFUND Act of 2019 -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. -Issues related to healthcare legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program - Drug pricing issues - Prescription Drug User Fee Act reauthorization
H.R.2209 - Fixing Global Freeloading Act - Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; -Issues related to the 340B Drug Discount Program -Issues relating to drug pricing -Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. -Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. -General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
H.R.3 - Lower Drug Costs Now Act of 2019 Prescription Drug Pricing Reduction Act (PDPRA) of 2019 S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. -Issues related to Medicare and Medicaid coverage and reimbursement -Issues related to the 340B Drug Discount Program -Issues related to drug pricing -Medicare reimbursement for biosimilars -MACRA treatment and reimbursement of Part B drugs -Medicare payments for inpatient antimicrobials -Issues related to drug importation
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor, Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 H.R.3164, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2020 and H.R.3055, the FY2020 Consolidated measure. H.R.2740, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2020 and he FY2020 Consolidated measure. Reimbursement and vial size issues. - Issues related to FDA and HHS program funding for the FY20 Labor, HHS, Education and Related Agencies, and FY20 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
S.977 - Transparent Drug Pricing Act of 2019 H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities Act (340B PAUSE Act) S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 Part D Medicare Program (including Coverage Gap and other offsets in H.R.1892/P.L.115-123, Bipartisan Budget Act of 2018). HR 4392 - reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6071 - SERV Communities Act HR 6240 - Drug Discount Accountability Act (user fees) S.3787 - DISARM Act of 2018 H.R. 7077, the Restoring the Patients Voice Act S.551, REFUND Act of 2019 H.R. 1520, the Purple Book Continuity Act H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act H.R. 965, the CREATES Act H.R.269/S.1379, Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2019 (P.L.116-22). S.1895, Lower Health Care Costs Act of 2019. - Issues related to Medicare and Medicaid coverage and reimbursement - Issues related to the 340B Drug Discount Program - Issues related to drug pricing - Medicare reimbursement for biosimilars - MACRA treatment and reimbursement of Part B drugs - Medicare payments for inpatient antimicrobials - Issues related to drug importation - Issues related to the International Pricing Index for Medicare Part D
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing.
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to antimicrobial and antiviral research and product development
S.1416 - Affordable Prescriptions for Patients Act of 2019 S.659 - Biologic Patent Transparency Act S. 1227, Prescription Pricing for the People Act of 2019 S. 1224, Stop STALLING Act - Intellectual property and process patent issues - Patent litigation reform - IPR process - Section 101 Reform
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
- Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
- Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor , Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; H.J.Res.31, Consolidated Appropriations Act, 2019 (P.L.116-6); FY 2020 - Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 H.R. 2113 - The Prescription Drug STAR Act H.R. 1520, the Purple Book Continuity Act; H.R. 1503, the Orange Book Transparency Act; H.R. 1499, the Protecting Consumer Access to Generic Drugs Act; and H.R. 965, the CREATES Act; - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety, and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement, and pricing. - Issues related to healthcare legislation
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
- Drug pricing issues - Prescription Drug User Fee Act reauthorization - HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 S.204/H.R.878, Trickett-Wendler Right to Try Act of 2017 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 - Issues related to the 340B Drug Discount Program - Issues relating to drug pricing - Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. - Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. - General education about policies impacting pharmaceutical development, approval, reimbursement and pricing. - Issues related to healthcare legislation
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 - Issues related to public health protection including influenza development and preparedness - Issues related to Right to Try - Issues related to antimicrobial and antiviral research and product development
H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245) S. 3158, Department of Labor , Health & Human Services, and Education, and Related Agencies Appropriations Act of 2019; - Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
S.3158/H.R.6470, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2019; H.R.5961/S.2976, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2019; H.R. 1892, the Bipartisan Budget H.R. 1625, Consolidated Appropriation Act H.R.6157, Department of Defense and Labor, Health and Human Services, and Education Appropriations Act, 2019 and Continuing Appropriations Act, 2019 (P.L.115-245); Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Issues related to Direct-To-Consumer Advertising, 340B, biosimilars, and public health
H.R. 4710 - 340B Protecting Access for the Underserved and Safety-Net Entities (PAUSE) Act S. 2312 - The Helping Ensure Low-income Patients have Access to Care and Treatment Act S. 2453 - Ensuring the Value of the 340B Program Act of 2018 HR 4392 - Reversing the HOPPS rule reimbursement cut to 340B hospitals HR 5598 - 340B Optimization Act HR 2889 - Closing Loopholes for Orphan Drugs Act HR 6240 - Drug Discount Accountability Act (user fees) H.R.6071 - SERV Communities Act of 2018 P.L.109-417, Pandemic and All-Hazards Preparedness Act (PAHPA) S.2852 - Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R. 6378 - To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act H.R.6294 - Re-Valuing Anti-Microbial Products (REVAMP) Act of 2018 S.974 - CREATES Act of 2017 Issues related to the 340B Drug Discount Program Issues relating to drug pricing, reimbursement, step therapy, anti-kickback statute, biosimilars Development of policies to advance antimicrobial research, antiviral research, and novel product development environment, including advancing new market incentives. Issues and policies relating to the Food and Drug Administration including biopharmaceutical development, drug safety and counterfeiting, and biosimilars. General education about policies impacting pharmaceutical development, approval, reimbursement and pricing
Drug Pricing Issues HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 H.R. 6378 - To reauthorize certain programs under the Pandemic and All-Hazards Preparedness Reauthorization Act Issues related to public health protection including influenza development and preparedness Issues related to antimicrobial and antiviral research and product development
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
H.R. 3358/S 1771 Departments of Labor, Health, and Human Services, and Education, and Related Agencies Appropriations Act, 2018 H.R.3268/S.1603, Agriculture, Rural Development, Food, and Drug Administration, and Related Agencies Appropriations Act, 2018 H.R.1370, Further Additional Continuing Appropriations Act, 2018 H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 Issues related to FDA and HHS program funding for the FY18 Labor, HHS, Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Issues related to FDA and HHS program funding for the FY19 Labor, HHS, Education and Related Agencies, and FY19 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
S. 2852 Pandemic and All-Hazards Preparedness and Advancing Innovation Act of 2018 Issues related to public health protection including influenza development and preparedness Issues related to Right to Try Issues related to antimicrobial and antiviral research and product development
Drug Pricing Issues HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
Issues relating to trade policy and negotiations impacting the biopharmaceutical industry
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Drug Pricing Issues Prescription Drug User Fee Act reauthorization. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
H.R.3358/S.1771, Departments of Labor, Health, and Human Services, and Education, and Related Agencies Appropriations Act, 2018 H.R.3268/S.1603, Agriculture, Rural Development, Food, and Drug Administration, and Related Agencies Appropriations Act, 2018 H.R.1370, Further Additional Continuing Appropriations Act, 2018 H.R.1892, Bipartisan Budget Act of 2018 H.R.1625, Consolidated Appropriations Act, 2018 Issues related to FDA and HHS program funding for the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills Issues related to FDA and HHS program funding for the FY19 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food, and Drug Administrations, and Related Agencies Appropriation bills
Issues related to Right to Try
Trade Policy Issues. Trade Negotiations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Issues related to FDA and HHS program funding in the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Development, Food and Drug Administrations, Related Agencies Appropriation bills
Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Issues related to Medicare and Medicaid coverage and reimbursement; Issues relating to biosimilar reimbursement; Issues related to RX drug pricing. Medicare payment for inpatient antimicrobial therapy.
Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 S.204/H.R.878, Trickett Wendler Right to Try Act of 2017 H.J.Res.123, Making further continuing appropriations for fiscal year 2018, and for other purposes H.J.Res.124, Making further additional continuing appropriations for fiscal year 2018, and for other purposes H.R.1370, Further Additional Continuing Appropriations Act, 2018 Pharmaceutical benefits for TRICARE beneficiaries Issues related to pharmaceutical drug pricing Development of policies to advance the antimicrobial research and novel product development environment, including advancing new market incentives. Pharmaceutical distribution and supply chain security American Health Care Act of 2017 Issues relating to biosimilar reimbursement
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Medicare payment policies for Part B drugs. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program CHIP reauthorization and Medicare Extenders package. Issues related to Medicare and Medicaid coverage and reimbursement; Issues relating to biosimilar reimbursement; Issues related to RX drug pricing. Medicare payment for inpatient antimicrobial therapy.
Drug Pricing Issues Prescription Drug User Fee Act reauthorization. HR 4710, 340B Pause Act and other issues relating to the 340B Drug Discount Program
Issues related to FDA and HHS program funding in the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Development, Food and Drug Administrations, Related Agencies Appropriation bills
Trade Policy Issues. Trade Negotiations.
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, White House Office
Trade Policy Issues. Trade Negotiations.
H.R. 1628 American Health Care Act of 2017; Better Care Reconciliation Act; General education, guidance and strategic counsel about policies impacting pharmaceutical development, approval and reimbursement; H.R. 2430/S. 934, FDA Reauthorization Act of 2017 General education about FDA approval policies including pediatric trial design, and right-to-try proposals Advocated to include market incentives for antimicrobials in H.R. 2430 / S. 934 - FDA Reauthorization Act of 2017 Implementation issues related to the Pharmaceutical Quality, Security and Accountability Act (P.L. 113-54) Issues related to drug pricing Education around issues relating to the 340B Drug Discount Program Issues related to FDA and HHS program funding in the FY18 Labor, Health and Human Services, and Education and Related Agencies, and FY18 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriation bills
Issues relating to drug pricing Education on policies pertaining to the 340B Drug Discount Program
Filing targets: Centers For Medicare and Medicaid Services (CMS), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, Treasury, Dept of, White House Office
Implementation of Medicare pharmaceutical coverage and reimbursement issues Policies relating to 340B Drug Discount Program Issues relating to the repeal and replacement of the Affordable Care Act (HR 1628, The American Health Care Act). Medicare Part B reimbursement issues for physicians and implementation of related provisions of MACRA Payment policies for prescription drugs
Trade negotiations, Transatlantic Trade and Investment Partnership (TTIP), NAFTA. Issues related to trade policy.
Issues related to the development of medical countermeasures for neurotoxins; Biomedical Advanced Research and Development Authority
Issues related to FDA and HHS program funding in the FY17 Labor, Health and Human Services, and Education and Related Agencies, and FY17 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriations bills. FY2018, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; FY2018, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations; H.R.244, Consolidated Appropriations Act 2017 (P.L.115-31); vial size issues. Issues related to establishing the budget for the United States Government for FY 2018, Bipartisan Budget Act of 2015
Filing targets: Centers For Medicare and Medicaid Services (CMS), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), Office of Management & Budget (OMB), SENATE, White House Office
Trade negotiations and Transatlantic Trade Partnership (TTIP). Issues related to trade policy.
Bioterrorism preparedness and development of medical countermeasures.
Implementation of Medicare pharmaceutical coverage and reimbursement issues; Medicare Part B reimbursement for physicians and implementation of related provisions of the Affordable Care Act; reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B drug payment model. Policies relating to 340B Program. Issues relating to the repeal and replacement of the Affordable Care Act (HR 1628, The American Health Care Act).
Provide guidance and strategic counsel with regard to regulations and legislation that could impact, pharmaceutical and biotechnology manufacturers. Policies related to the 340B Drug Discount Program. Drug pricing issues. HR 1628, The American Health Care Act. S. 469 Affordable and Safe Prescription Drug Importation Act. Prescription Drug User Fee Act Agreements. S.204/H.R.878, Trickett Wendler Right to Try Act of 2017. Issues related to the implementation of the follow-on biologics provisions in P.L. 111148 "Patient Protection and Affordable Care Act". Stockpiling of medical countermeasures in advance of a potential pandemic. Implementation of issues related to the Security and Accountability Act (P.L. 113-54); Issues related to Pharma supply chain.
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Trade negotiations and Transatlantic Trade Partnership (TTIP). Issues related to trade policy.
Implementation of Medicare pharmaceutical coverage and reimbursement issues; Medicare Part B reimbursement for physicians and implementation of related provisions of the Affordable Care Act; reimbursement adequacy and patient access issues associated with potential CMMI implementation of the proposed Medicare Part B drug payment model. Policies relating to 340B Program. Issues relating to the repeal and replacement of the Affordable Care Act (HR 1628, The American Health Care Act).
Intellectual Property and Process Patent Issues. Patent Litigation Reform.
Issues related to FDA and HHS program funding in the FY17 Labor, Health and Human Services, and Education and Related Agencies, and FY17 Agriculture, Rural Developments, Food and Drug Administrations, and Related Agencies Appropriations bills.
Monitor Drug Safety and pedigree legislation. 340B Drug Discount Program.
Filing targets: Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE
Intellectual Property and Process Patent Issues. General IP Issues; Patent Litigation Reform; Transpacific Partnership Agreement.
S 3040/HR5926, Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations Act, 2017. H.R.5054/S.2956, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2017. Appropriations for Biosecurity Preparedness; HCR/CDC/HHS - Replenishment of Influenza Antiviral Stockpile.
Filing targets: Centers For Disease Control & Prevention (CDC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
H.R. 6 21st Century Cures Act. Innovation for Healthier Americans -- Senate HELP Committee. Implementation issues related to Pharmaceutical Quality Quality, Security & Accountability Act (PL 113-54). Issues related to the 340B Drug Discount Program. Drug pricing issues. White House Cancer Moonshot & Precision Medicine initiatives. Part B Drug payment issues, CMMI Part B Payment model. Issues related to the implementation of the follow-on biologies provisions in P.L. 11-1148 "PPACA". S.2912, Trickett Wendler Right to Try Act of 2016. Pandemic Preparedness and CDC strategic national stockpile H.R.5122 - To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models.
Filing targets: Centers For Disease Control & Prevention (CDC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)
Implementation of the Pharmaceutical, Quality, Safety & Accountability Act (P.L. 113-54). 340B drug discount program.
Intellectual Property and Process Patent Issues. General IP Issues; Patent Litigation Reform; Transpacific Partnership Agreement.
Issues relating to CMMI proposed CMMI Part B demo (81 FR 13229) 340B drug discount program. 21st Century Cures initiative. Implementation of Medicare Pharmaceutical coverage and reimbursement. Follow-on biologies and Medicare Physician Fee schedule rule to blend ASP for biosimilars.
Filing targets: Centers For Disease Control & Prevention (CDC), Executive Office of the President (EOP), Food & Drug Administration (FDA), HOUSE OF REPRESENTATIVES, Health & Human Services, Dept of (HHS), SENATE, U.S. Trade Representative (USTR)